# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening. **S**

## Objective

Hemoglobin: 12.4 g/dL; MCV: 101 fL (high); Platelets: 236 10*3/uL; Sodium: 138 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.72 mg/dL; eGFR: 113 mL/min/1.73 m²; Glucose: 88 mg/dL; AST: 52 U/L (high); ALT: 38 U/L; GGT: 84 U/L (high); Albumin: 4 g/dL; Total bilirubin: 0.7 mg/dL; Hepatitis C antibody (signal-to-cutoff): 0.09; Hepatitis B surface antibody: 3 m[IU]/mL (low); Phosphatidylethanol (PEth): 312 ng/mL (high); PHQ-9: 9; AUDIT-C: 8; DAST-10: 7. All results are synthetic.

BP 126/80 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 68 kg; BMI 25 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use; Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily **S**
- Started: Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Started: Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Plan

- Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test strips. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Addiction medicine consultation to confirm the medication plan, choose a medicine for alcohol use disorder that can be used with buprenorphine, and set the monitoring plan. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immune. Guideline: Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020); Human Immunodeficiency Virus (HIV) Infection: Screening (2019) **S**
- Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
